4.8 Article

Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage

期刊

SCIENCE
卷 342, 期 6160, 页码 866-871

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1243292

关键词

-

资金

  1. European Research Council (ERC) [260477]
  2. European Union (EU) [261441]
  3. National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre
  4. Swiss National Science Foundation [PA00P3_134202]
  5. European Commission [275880]
  6. Medical Research Council [U105184308]
  7. National Children's Research Centre, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland
  8. Wellcome Trust
  9. Medical Research Council UK
  10. British Lung Foundation
  11. Biotechnology and Biological Sciences Research Council [BB/J004456/1]
  12. Institut National de la Sante et de la Recherche Medicale
  13. EU FP7 EUROPAD [201549]
  14. Association Contre Le Cancer
  15. Agence Nationale de la Recherche [2010-CSRD]
  16. EU FP7 ERC PIDIMMUNE [249816]
  17. PASPA-DGAPA-UNAM
  18. GlaxoSmithKline
  19. Roche
  20. Novartis
  21. Karus Therapeutics Ltd
  22. Biotechnology and Biological Sciences Research Council [BBS/E/B/000C0411, BBS/E/B/0000H260, BBS/E/B/0000H329] Funding Source: researchfish
  23. Medical Research Council [MC_U105184308] Funding Source: researchfish
  24. Swiss National Science Foundation (SNF) [PA00P3_134202] Funding Source: Swiss National Science Foundation (SNF)
  25. BBSRC [BBS/E/B/0000H260, BBS/E/B/0000H329, BBS/E/B/000C0411] Funding Source: UKRI
  26. MRC [MC_U105184308] Funding Source: UKRI

向作者/读者索取更多资源

Genetic mutations cause primary immunodeficiencies (PIDs) that predispose to infections. Here, we describe activated PI3K-delta syndrome (APDS), a PID associated with a dominant gain-of-function mutation in which lysine replaced glutamic acid at residue 1021 (E1021K) in the p110 delta protein, the catalytic subunit of phosphoinositide 3-kinase delta (PI3K delta), encoded by the PIK3CD gene. We found E1021K in 17 patients from seven unrelated families, but not among 3346 healthy subjects. APDS was characterized by recurrent respiratory infections, progressive airway damage, lymphopenia, increased circulating transitional B cells, increased immunoglobulin M, and reduced immunoglobulin G2 levels in serum and impaired vaccine responses. The E1021K mutation enhanced membrane association and kinase activity of p110 delta. Patient-derived lymphocytes had increased levels of phosphatidylinositol 3,4,5-trisphosphate and phosphorylated AKT protein and were prone to activation-induced cell death. Selective p110 delta inhibitors IC87114 and GS-1101 reduced the activity of the mutant enzyme in vitro, which suggested a therapeutic approach for patients with APDS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据